5Pienta ICI. Critical appraisal of prostate-specific antigen in prostate screening:20 years laster. Urology 2009; 73(5 Suppl): S11-S20.
6Schrder FH, Hugosson J, Roobol M J, et al. Screening and prostatecancer in a randomized European study. NEngl J Meal2009; 360(13): 1320-1328.
7Veltri RW, Miller MC, Oflowd GJ, eta1. Impact of age on total and complexed prostate- specific antigen cutoffs in acontemperary referral series of men with prostate cancer. Urology 2002; 60(4Suppl 1): 47-52.
8Nadler RB, Humphrey PA, Smith DS, et al. Effect ofintlammation and benign pro- static hyperplasia on elevated serum prostate-specific antigen levels. J Urol 1995; 154(2 Pt 1): 407-413.
9Hodge KK, Mcneal J E, Stamey TA. U Ltrasoundguided transrectal core biopsies of the pa-lpably abnormal prostate. J Urol 1989; 142(1): 66-70.
10Ravery V, Billebaud T, Toublanc M, et al. Diagnostic value of ten systematic TRUS- guided ptostate biopsies. Eur Urol 1999; 35(4): 298-303.
8Hodge KK, McNeal JE, Terris MK, et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142(1): 71-74.
